These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11365822)

  • 1. Potential interactions between cholesterol lowering drugs and protease inhibitors.
    Notes Undergr; 1998; (No 37):8. PubMed ID: 11365822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A further point about statins...
    Gilden D
    GMHC Treat Issues; 1998 Jun; 12(6):8. PubMed ID: 11365725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
    Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
    Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy.
    Moyle GJ; Buss NE; Gazzard BG
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):460-2. PubMed ID: 12138355
    [No Abstract]   [Full Text] [Related]  

  • 6. Protease inhibitors and lipid-lowering drugs--interactions.
    TreatmentUpdate; 2002 Mar; 14(3):7-8. PubMed ID: 12033192
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
    Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
    Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone, adherence and protease inhibitors.
    Treat Rev; 1997 Aug; (No 25):2-3. PubMed ID: 11364614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV protease inhibitors and dyslipidemia.
    Clotet B; Negredo E
    AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease problems.
    Price J
    STEP Perspect; 1998; 98(3):3-5. PubMed ID: 11365827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease inhibitor side effects take people by surprise.
    Huff A
    GMHC Treat Issues; 1997-1998 Winter; 12(1):25-7. PubMed ID: 11364985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double jeopardy: the hazards of drug-drug interactions.
    Flexner C
    Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drugs and the risk of myocardial infarction.
    Zangerle R; Sarcletti M
    N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.